| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| ASU 2014-09 | 394.8 | | | | | | | |
| Product | 394.1 | 340.5 | 326.9 | | | | | |
| Invasive breast cancer test | 358.2 | | | | | | | |
| United States | 334.7 | 287.7 | 281.1 | 246.0 | 230.7 | 223.7 | 207.5 | 187.3 |
| Other | | | | 41.5 | 45.0 | 37.9 | 27.7 | 18.8 |
| Total revenues [+] | 394.1 | 340.8 | 327.9 | 287.5 | 275.7 | 261.6 | 235.2 | 206.1 |
| Royalties | | | | | | | 49.1 | 39.9 |
| Products | | | | 287.5 | 275.7 | 259.2 | 233.5 | 204.8 |
| Contracts | | | | | | 2.4 | 1.7 | 1.3 |
| Revenue growth [+] | 15.7% | 3.9% | 14.1% | 4.3% | 5.4% | 11.2% | 14.1% | 15.7% |
| Product | 15.8% | 4.1% | | | | | | |
| United States | 16.3% | 2.3% | 14.3% | 6.7% | 3.1% | 7.8% | 10.8% | 11.5% |
| International | 11.9% | 13.5% | 12.9% | -8.0% | 18.8% | 37.1% | 47.1% | 86.6% |
| Cost of goods sold | 64.3 | 54.7 | 58.8 | 55.1 | 48.7 | 42.1 | 37.0 | 33.8 |
| Gross profit | 329.8 | 286.0 | 269.0 | 232.3 | 227.0 | 219.5 | 198.2 | 172.3 |
| Gross margin | 83.7% | 83.9% | 82.1% | 80.8% | 82.3% | 83.9% | 84.3% | 83.6% |
| Selling, general and administrative [+] | 241.7 | 229.7 | 224.3 | 207.9 | 197.5 | 167.2 | 140.6 | 124.2 |
| Sales and marketing | 164.8 | 157.0 | 151.0 | 143.6 | 137.8 | 112.8 | 93.6 | 83.6 |
| General and administrative | 76.9 | 72.7 | 73.3 | 64.3 | 59.7 | 54.4 | 47.1 | 40.5 |
| Research and development | 64.2 | 62.8 | 60.2 | 58.4 | 53.1 | 64.2 | 49.1 | 39.9 |
| EBITDA [+] | 36.6 | 5.3 | -6.5 | -27.0 | -16.8 | -5.5 | 13.9 | 15.6 |
| EBITDA growth | 588.7% | -181.7% | -75.9% | 60.9% | 204.2% | -139.6% | -10.7% | 40.2% |
| EBITDA margin | 9.3% | 1.6% | -2.0% | -9.4% | -6.1% | -2.1% | 5.9% | 7.6% |
| Depreciation and amortization | 12.7 | 11.8 | 8.9 | 7.1 | 6.9 | 6.3 | 5.5 | 7.3 |
| EBIT [+] | 23.9 | -6.5 | -15.4 | -34.0 | -23.6 | -11.8 | 8.4 | 8.3 |
| EBIT growth | -470.5% | -58.2% | -54.6% | 44.0% | 99.7% | -240.3% | 2.1% | 110.5% |
| EBIT margin | 6.1% | -1.9% | -4.7% | -11.8% | -8.6% | -4.5% | 3.6% | 4.0% |
| Interest income | 2.4 | 0.9 | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 |
| Interest income | 2.4 | 0.9 | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | 0.2 |
| Other income (expense), net [+] | 0.6 | 3.2 | 2.5 | -0.5 | -0.8 | -0.8 | -0.1 | -0.2 |
| Impairment of investments | | | | | | -0.6 | | |
| Other | -0.2 | 0.3 | -0.7 | -0.5 | -0.8 | -0.2 | -0.1 | -0.2 |
| Pre-tax income | 26.9 | -2.4 | -12.5 | -34.3 | -24.2 | -12.4 | 8.7 | 8.3 |
| Income taxes | 1.2 | 1.5 | 1.4 | -1.0 | 0.4 | 0.3 | 0.4 | 0.4 |
| Tax rate | 4.6% | | | 2.9% | | | 4.9% | 5.2% |
| Net income | 25.7 | -3.9 | -13.9 | -33.3 | -24.6 | -12.8 | 8.2 | 7.8 |
| Net margin | 6.5% | -1.1% | -4.2% | -11.6% | -8.9% | -4.9% | 3.5% | 3.8% |
| |
| Basic EPS [+] | $0.72 | ($0.11) | ($0.42) | ($1.03) | ($0.78) | ($0.42) | $0.27 | $0.27 |
| Growth | -742.8% | -73.3% | -59.3% | 31.6% | 87.0% | -253.7% | 1.9% | 79.4% |
| Diluted EPS [+] | $0.68 | ($0.11) | ($0.42) | ($1.03) | ($0.78) | ($0.42) | $0.26 | $0.26 |
| Growth | -711.5% | -73.3% | -59.3% | 31.6% | 87.0% | -263.0% | 0.6% | 76.4% |
| |
| Shares outstanding (basic) [+] | 35.7 | 34.5 | 33.3 | 32.4 | 31.5 | 30.5 | 30.3 | 29.4 |
| Growth | 3.6% | 3.7% | 2.7% | 3.0% | 3.1% | 0.6% | 3.2% | 2.0% |
| Shares outstanding (diluted) [+] | 37.6 | 34.5 | 33.3 | 32.4 | 31.5 | 30.5 | 32.2 | 30.8 |
| Growth | 8.9% | 3.7% | 2.7% | 3.0% | 3.1% | -5.1% | 4.5% | 3.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |